Simoa® accelerator laboratory

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

request more info

SIMOA® in Action

Learn how we advance access to the biology of the brain

see related case study

Our Culture

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health.

The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

How it Works

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate, felis tellus mollis orci, sed rhoncus pronin sapien nunc accuan eget.The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

  • Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.
  • Detection antibodies – capable of generating fluorescent product – are added.
  • The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
  • At low concentrations, each bead will contain one bound protein, or none.
  • The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

Work With Us

Section without icons on the right and with CTA below text here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate, felis tellus mollis orci, sed rhoncus pronin sapien nunc accuan eget.The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

Field Applications Scientists

  • Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.
  • Detection antibodies – capable of generating fluorescent product – are added.
  • The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.
  • At low concentrations, each bead will contain one bound protein, or none.
  • The sample is loaded into arrays, in the Simoa disc, consisting of more than 200,000 microwells – each large enough to hold one bead.

Detecting the Undetectable

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

First of its kind detection capabilities

This innovative technology is perfectly suited for single- and multi-plex detection of key biomarkers at ultra-low levels in applications within all therapeutic areas, including oncology, neurology, cardiology, immunology, and infectious disease.

Detect biomarkers at femtogram levels

The innovative digital nature of the technique allows an average of 1000 times sensitivity increase over conventional assays, with CVs less than 10 percent.

See results in record time

Incubation time for analyte capture and detector binding is typically about 30 minutes, with five minutes for labeling by the streptavidin β-galactosidase (SBG) conjugate.

Benefits of Working With Us

will be replaced with SVG

Health, dental, life insurance

will be replaced with SVG

Flexible spending plan

will be replaced with SVG

Paid vacation

will be replaced with SVG

Stock options

will be replaced with SVG

401(k) investment plan

See Also

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

Customer Care

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Tech Support

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Field Service Engineer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Field Applications Scientists

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor.

Meet the Team

Let Us Tell You

“I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith, the Corporation Company

“2 I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith 2, the Corporation Company 2

“3 I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith 3, the Corporation Company 3

“4 I was truly amazed by the Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.”

John Smith 4, the Corporation Company 4

services

Quanterix Solutions

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet.

Quanterix Assays

Our broad portfolio of available kits spans multiple therapeutic areas including cardiology, infectious disease, inflammation, neurology, and oncology. Choose from our readily-available kits or our homebrew option.

SIMOA Bead Technology

Simoa means sensitivity. Find out how Quanterix’ Simoa Bead Technology is changing the way in which the biology of health and disease is studied.

learn more

Planar Array Technology

With Simoa Senstivity™, Quanterix’ Planar Array Technology now gives researchers an incredibly simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.

learn more

Uman Diagnostics Assays & Reagents

Our broad portfolio of available kits spans multiple therapeutic areas including cardiology, infectious disease, inflammation, neurology, and oncology. Choose from our readily-available kits or our homebrew option.

SIMOA Bead Technology

Simoa means sensitivity. Find out how Quanterix’ Simoa Bead Technology is changing the way in which the biology of health and disease is studied.

learn more

Planar Array Technology

With Simoa Senstivity™, Quanterix’ Planar Array Technology now gives researchers an incredibly simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.

learn more

Oncology

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research. Simoa® assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

see related assays

Neurology

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed. Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL),Tau, GFAP and several otohers associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers & pharmaceutical and biotech partners to drive advancements in head health research.

see related assays

Brain Derived Neurotrophic Factor (BDNF)

Brain Derived Neurotrophic Factor (BDNF) is a member of the neurotrophin family, which includes NGF, NT-3, and NT-4/5. This family is likely derived from a common ancestral gene and share similar sequences and structures.

BDNF has a molecular weight of ~27 kDa and exists as a homodimer. It shares a common cysteine knot structure with the other members of the neurotrophin family. BDNF has a precursor peptide known as proBDNF, and during processing the cleaved pro-domain is packaged and co-secreted with the mature BDNF form. The effects of proBDNF are less defined than those of the mature BDNF form. BDNF’s effects are mostly mediated through the TrkB receptor, though it can also bind to a pan-neurotrophin receptor known as p75. BDNF is associated with almost all aspects of the nervous system, promoting neuronal survival and differentiation, modulating synaptic plasticity, synapse formation, neuronal excitability, LTP, etc. It has important roles within the development of the nervous system into adulthood. Several studies have demonstrated possible links to various disease states and conditions including: Alzheimer’s disease, OCD, depression, Huntington’s disease, schizophrenia and dementia.

SIMOA® Accelerator Lab by the Numbers

0

Customers to Date

0

Samples Run to Date

0

Projects to Date

Total Biomarker Assays

0

Oncology

0

Neurology

0

Immunology

0

Cardiology

0

Infectious Disease

Products Mentioned

Sociis Natoque
Request a Quote
Penatibus Et Magnis
Request a Quote
Dis Parturient Montes
Request a Quote
Nascetur Ridiculus Mus
Request a Quote

Our Mission & Vision

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet

Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate, felis tellus mollis orci, sed rhoncus pronin sapien nunc accuan eget.

  • Proin gravida dolor sit amet lacus accumsan et viverra justo commodo.
  • Proin sodales pulvinar sic tempor.
  • Sociis natoque penatibus et magnis dis parturient monte.
meet the team

Kevin Hrusovsky

President, Chairman and Chief Executive Officer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet. Proin gravida dolor sit amet lacus accumsan et viverra justo commodo. Proin sodales pulvinar sic tempor. Sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nam fermentum, nulla luctus pharetra vulputate.

Ready to take your biomarker research to the next level?

request a quote

Let Us Show You

Simoa® assays by the numbers

Quanterix’ Simoa technology is changing the way in which the biology of health and disease is studied by giving researchers the ability to closely examine critical biomarkers.

In doing so, this game-changing technology enables the development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

See Also

Simoa, an ultra-sensitive immunoassay technology allows detection of proteins and nucleic acids at lowest possible levels.

Delivering Ultrasensitive Biomarker Measurement

Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform. Leveraging years of experience with the ground-breaking Simoa HD-1 Analyzer, the new flagship HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

read more

Delivering Ultrasensitive Biomarker Measurement 2

Quanterix 2 is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform. Leveraging years of experience with the ground-breaking Simoa HD-1 Analyzer, the new flagship HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

read more

Does your research focus on neuropathy associated with SARS-Cov-2 infection?

Check out the extensive neurology menu on HD-X and SR-X providing the same level of sensitivity and precision as SPX for your cytokine research

Delivering Ultrasensitive Biomarker Measurement You Can Count On.

Quanterix is re-engineering ultrasensitivity with the launch of the Simoa HD-X Analyzer™, the latest model fully automated Simoa bead-based immunoassay platform. Leveraging years of experience with the ground-breaking Simoa HD-1 Analyzer, the new flagship HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

Ultra-sensitivity

Up to 1000x greater sensitivity than traditional immunoassays

Automation

Reproducibility and convenience of sample-answer workflow

Regulatory Compliance

Enables 21CFR Part 11 compliance with streamlined run reports and user management

Automation

Reproducibility and convenience of sample-answer workflow

Ultra-sensitivity

Up to 1000x greater sensitivity than traditional immunoassays

Automation

Reproducibility and convenience of sample-answer workflow

Video about SIMOA Technology

We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. In our focused therapeutic areas, our revolutionary technology is helping researchers advance the science of precision health.

Watch our one minute video

Quanterix’ proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

learn more
Will be replaced with SVG

Watch our one minute video

Quanterix’ proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

learn more

Watch our one minute video

Quanterix’ proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents.

Watch our one minute video

learn more

Watch our one minute video

Here Goes the Title

Using simple, well-established chemistry, researchers can explore significant unmet needs in life science research using digital biomarker analysis technology.

Using simple, well-established chemistry, researchers can explore significant unmet needs in life science research using digital biomarker analysis technology. Quanterix also provides the option of developing multiplex homebrew assays to minimize the sample volume, providing full kits that include all reagents and training required to develop these custom homebrew assays. The LONGTERMS study evaluated the safety and efficacy of fingolimod in patients with relapsing MS (RMS) with up to 14 years of exposure. This phase IIIb, open-label extension study included patients aged 18 years with confirmed RMS diagnosis who completed previous phase II/III/IIIb core/extension studies of fingolimod.

Conclusion

The LONGTERMS study evaluated the safety and efficacy of fingolimod in patients with relapsing MS (RMS) with up to 14 years of exposure. This phase IIIb, open-label extension study included patients aged 18 years with confirmed RMS diagnosis who completed previous phase II/III/IIIb core/extension studies of fingolimod. Patients received fingolimod 0.5 mg orally once daily; safety and efficacy (clinical and magnetic resonance imaging) were the main outcomes.

SIMOA® Accelerator Laboratory

Greater depths of contract research at your reach

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The SIMOA Accelerator Laboratory

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection
  • Infrastructure allows scalability to handle sample sets
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope
  • Onsite assay development training through a 4-day program

SIMOA® Accelerator Laboratory

Greater depths of contract research at your reach

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The SIMOA Accelerator Laboratory

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection
  • Infrastructure allows scalability to handle sample sets
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope
  • Onsite assay development training through a 4-day program

contact us

900 Middlesex Turnpike, Building 1 Billerica, MA 01821 USA

+1 (617) 301-9400

see detailed contact info

Our International Distributors

Japan

ffsdfsdf
Tel: 2352352352Fax: 324243235253

Singapur

asdasdasd
Tel: adsasd

Kevin Hrusovsky

Chairman, Chief Executive Officer, President

Kevin Hrusovsky is an American biotech entrepreneur, engineer, and healthcare visionary who has dedicated his 30-year career to transforming medicine from reactive “sick care” to preventative and personalized healthcare.

Hrusovsky is leading the charge to establish a new paradigm for healthy living based on peer-reviewed science that addresses the continuum from health to disease at the molecular structure level in the human body. He catalyzed a precision health movement that began in 2008 with the launch of the Revolutionaries for Global Health Summit Series to promote innovation for eradicating disease and personalizing global health. In 2016, Hrusovsky founded Powering Precision Health, the annual summit that quickly become the industry’s leading platform and premier forum for advancing the deep science that powers precision health.

An acclaimed life sciences and healthcare authority, Hrusovsky is regularly asked to provide both in-depth analysis and the big picture view on achieving industry-wide transformation to true precision medicine. He has been a featured guest on numerous media outlets, including ABC’s Good Morning America, CBS, NBC, CNN, CNBC, NPR Science Friday, USA Today, Forbes, Fortune, Bloomberg, Wall Street Journal, New York Times, International Business Times, Washington Post, STAT, Quartz, HuffPost, The Guardian, Scientific American, Boston Globe, Wired, and Fast Company.

Hrusovsky has been recognized with many awards and accolades, including a 2017 BBJ Innovation All-Star award for transforming the practices of medicine and health. He is a three-time Award Finalist of the EY Entrepreneur of the Year® (2007, 2017 and 2018) and received the Lifetime Achievement Award for Leadership (2018) and E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. In 2015, Hrusovsky was named a BostInno’s 50 on Fire Awards Finalist in Healthcare and Medicine.

A coveted thought leader and dynamic speaker, Hrusovsky is regularly invited to keynote and participate at leading conferences, executive summits and panel discussions, including the BIO International Convention, J.P. Morgan Healthcare Conference, One Mind Summit, Konkussion Retreat, PULSE: The Atlantic Summit on Health Care, MedCity CONVERGE, Next Generation Dx Summit, the annual conference of the Personalized Medicine Coalition, and World Innovation Forum.

He currently serves as President, Chairman and CEO of Quanterix, a company digitizing biomarker analysis to advance the science of precision health. In 2017, he took Quanterix public in one of the most successful IPOs for a life science tools company in recent history. Under his leadership, the company acquired Aushon and regained all rights and privileges associated with its groundbreaking Simoa technology through the termination of a license agreement with bioMérieux

Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer, CEO of Caliper Life Sciences (now PerkinElmer), and CEO of Zymark Corporation (now PerkinElmer). Previously, he served as President of FMC Corporation’s Pharmaceuticals and head of International Agricultural Products and held key management positions at E.I. DuPont de Nemours.

Hrusovsky is renowned for his strong track record of launching disruptive technologies, building fast-growing companies, and developing successful commercialization strategies. He lends his business expertise on the boards of innovative technology companies including BioreclamationIVT, Caliper Life Sciences, Cell Signaling Technology, 908 Devices, Cellaria, SeraCare, Synap Dx, Xenogen and Solect Energy. Hrusovsky is committed to education and serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston.

Hrusovsky holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University. He received an Honorary Doctorate from Framingham State University for his vast contributions in life sciences and personal medicine. In addition, he helped build competitive strategy curriculum at the Institute for Strategy & Competitiveness at Harvard Business School. Follow Kevin Hrusovsky on Twitter @KevinHrusovsky and LinkedIn @KevinHrusovsky.

William Geist

Chief Operating Officer

Will Geist has served as Chief Operating Officer from Quanterix since November 2020. Will is a proven, innovative, entrepreneur with a mission focused on improving the human condition through the power of science. With more than 25 years of experience, Will has an exceptional track record of developing and executing strategies that drive growth and fuel innovation. Having long admired Quanterix and the precision health movement, joining the team as the COO is a natural extension of Will’s life-time work. Prior to Quanterix, Will served as the Vice President and General Manager for two of Thermo Fisher Scientific’s largest business units; Protein and Cell Analysis (PCA) and qPCR. During this time, his teams developed and commercialized products across a broad range of proteomic and genomic technologies for research and clinical applications. He also served a key leadership role in Thermo Fisher Scientific’s Biosciences Division COVID-19 Task Force. Prior to Thermo Fisher, will held leadership roles with increasing responsibility at QIAGEN (Quanta BioSciences), Affymetrix, and Life Technologies. He holds a B.A. in Biology from Dartmouth College.

David Duffy, PhD

Vice President, Research and Chief Technology Officer

David joined Quanterix in 2007 and leads the team of scientists developing its single-molecule detection technology.
He is an inventor on 12 U.S. patents and has more than 20 publications in the fields of surface chemistry, microfluidics, and bioanalysis. He was previously at Surface Logix, where he was the Director of Pharmacomer Technology. There David oversaw the development of a novel chemical technology that resulted in two drug candidates currently in Phase II clinical trials. Prior to that, David was at Gamera Biosciences where he was a co-inventor of a centrifugal microfluidic that was acquired and commercialized by Tecan. He was a postdoctoral research fellow in the Department of Chemistry and Chemical Biology at Harvard University. David was the first Sir Alan Wilson Research Fellow of Emmanuel College, University of Cambridge, and holds a Ph.D. in Physical Chemistry from the Department of Chemistry at the University of Cambridge.

Mark Roskey, PhD

SVP, Strategic Partnerships

Mark joined Quanterix in mid 2014 as the Vice President and General Manager of Applications and Reagents. He has more than 25 years of experience in the life science industry focusing on product R&D, applications development, strategic sales and marketing, and overall business management for complex biological solutions and automated instrument systems. He comes to Quanterix from PerkinElmer’s LST division where he was VP/GM of the America’s Sales and Service organization. Prior to PerkinElmer, Mark held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011. Mark holds a Ph.D. in Microbiology from the University of Notre Dame and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.

Dawn R. Mattoon, PhD

Senior Vice President, Clinical Diagnostics

Dr. Dawn Mattoon joined Quanterix in February of 2018 as the Senior Vice President of Research Products, and has recently transitioned to serve as the Senior Vice President for Clinical Diagnostics. Dawn brings a strong breadth of experience in the biotechnology industry and has previously held leadership positions in R&D, Strategy, and General Management for companies including Invitrogen, Life Technologies, Thermo Fisher, and Cell Signaling Technologies. During this time she developed and commercialized products across a range of proteomic and genomic technologies including protein microarrays, next generation sequencing, antibodies, and high sensitivity immunoassays.

Mary Ellen Cortizas, JD

Vice President, CRO and Laboratory Services

Mary Ellen developed her operational expertise over a 30-year career at Boston Children’s Hospital. As Administrative Director of the Department of Laboratory Medicine, Mary Ellen had operational responsibility for clinical chemistry, hematology, microbiology, blood bank and molecular diagnostics. In addition to laboratory roles, Mary Ellen had active roles in enterprise-wide information technology, quality and regulatory management, emergency management, and strategic planning.

Prior to joining Quanterix, Mary Ellen was a founder and Chief Operating Officer at Claritas Genomics, a molecular genomics company dedicated to advancing precision care for pediatric rare disease. Claritas became the first clinical molecular diagnostic laboratory to achieve both ISO 15189 and New York State licensure for its unique exome-based diagnostics. Mary Ellen oversaw successful execution of a $9 million grant to sequence 20,000 exomes for the Veteran Adminstration’s Million Veterans project.

Mary Ellen has served on American Society of Clinical Pathologist Board of Registry exam committees, and is currently on the boards of two not-for-profit organizations focused on youth development.

Mary Ellen graduated from Suffolk Law School and holds a BA in Biology from Tufts University.

Denise Chittick

Chief Human Resources Officer

Denise joined Quanterix in January of 2021 as the Chief Human Resources Officer. She has over 25 years of experience bringing innovative human resources strategies to rapidly scaling international organizations in the medical device, consumer goods and SaaS industries. Most recently, she was the CHRO/VP of Human Resources for Reflexis Systems until it was acquired. Denise’s experience also includes global human resources leadership roles in several organizations where, among other things, she led projects encompassing acquisition integration, change management and organizational design. Denise holds a B.A. in Psychology from the University of Delaware, an M.A. in Psychology from Fairfield University and an M.B.A. from the University of Rhode Island.

Brian Keane, JD

Senior Vice President and Senior Legal Counsel

Brian Keane brings over 20 years of experience advising the management and boards of life sciences companies to his role as Vice President, Senior Legal Counsel of Quanterix. Prior to joining Quanterix, he was a Corporate & Securities Partner in the Life Sciences Practice at Mintz Levin. While at Mintz Levin, Mr. Keane served as outside counsel to dozens of life science companies, advising such clients on corporate governance, risk mitigation, SEC disclosure and compliance, financing transactions, M&A and strategic transactions, product development and commercialization and other matters. Mr. Keane holds a BS in electrical engineering from Tufts University and received his law degree from Boston College Law School.

John Fry, JD

General Counsel and Corporate Secretary

John joined Quanterix in 2019 and has over 25 years of experience as an attorney in the medical and technology industries. He previously served for over 10 years as Senior Vice President, General Counsel and Secretary of Analogic Corporation, a global supplier of medical and aviation security technology. Prior to joining Analogic, John was a principal in the law firm of Driggs, Hogg & Fry Co. L.P.A., where his practice focused primarily on technology and intellectual property law. He previously held various positions of increasing responsibility at Philips Medical Systems, including Senior Corporate Counsel and Intellectual Property Manager and counsel to Philips’ global computed tomography business. John began his career as an electrical engineer and engineering manager and is a named inventor on 10 U.S. patents. He holds bachelor’s and master’s degrees in electrical engineering from Case Western Reserve University and a law degree from Cleveland-Marshall College of Law.

Kevin Hrusovsky

Chairman, Chief Executive Officer, President

Kevin Hrusovsky is an American biotech entrepreneur, engineer, and healthcare visionary who has dedicated his 30-year career to transforming medicine from reactive “sick care” to preventative and personalized healthcare.

Hrusovsky is leading the charge to establish a new paradigm for healthy living based on peer-reviewed science that addresses the continuum from health to disease at the molecular structure level in the human body. He catalyzed a precision health movement that began in 2008 with the launch of the Revolutionaries for Global Health Summit Series to promote innovation for eradicating disease and personalizing global health. In 2016, Hrusovsky founded Powering Precision Health, the annual summit that quickly become the industry’s leading platform and premier forum for advancing the deep science that powers precision health.

An acclaimed life sciences and healthcare authority, Hrusovsky is regularly asked to provide both in-depth analysis and the big picture view on achieving industry-wide transformation to true precision medicine. He has been a featured guest on numerous media outlets, including ABC’s Good Morning America, CBS, NBC, CNN, CNBC, NPR Science Friday, USA Today, Forbes, Fortune, Bloomberg, Wall Street Journal, New York Times, International Business Times, Washington Post, STAT, Quartz, HuffPost, The Guardian, Scientific American, Boston Globe, Wired, and Fast Company.

Hrusovsky has been recognized with many awards and accolades, including a 2017 BBJ Innovation All-Star award for transforming the practices of medicine and health. He is a three-time Award Finalist of the EY Entrepreneur of the Year® (2007, 2017 and 2018) and received the Lifetime Achievement Award for Leadership (2018) and E.G. Bailey Entrepreneurship Award (2013), both from The Ohio State University. In 2015, Hrusovsky was named a BostInno’s 50 on Fire Awards Finalist in Healthcare and Medicine.

A coveted thought leader and dynamic speaker, Hrusovsky is regularly invited to keynote and participate at leading conferences, executive summits and panel discussions, including the BIO International Convention, J.P. Morgan Healthcare Conference, One Mind Summit, Konkussion Retreat, PULSE: The Atlantic Summit on Health Care, MedCity CONVERGE, Next Generation Dx Summit, the annual conference of the Personalized Medicine Coalition, and World Innovation Forum.

He currently serves as President, Chairman and CEO of Quanterix, a company digitizing biomarker analysis to advance the science of precision health. In 2017, he took Quanterix public in one of the most successful IPOs for a life science tools company in recent history. Under his leadership, the company acquired Aushon and regained all rights and privileges associated with its groundbreaking Simoa technology through the termination of a license agreement with bioMérieux

Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer, CEO of Caliper Life Sciences (now PerkinElmer), and CEO of Zymark Corporation (now PerkinElmer). Previously, he served as President of FMC Corporation’s Pharmaceuticals and head of International Agricultural Products and held key management positions at E.I. DuPont de Nemours.

Hrusovsky is renowned for his strong track record of launching disruptive technologies, building fast-growing companies, and developing successful commercialization strategies. He lends his business expertise on the boards of innovative technology companies including BioreclamationIVT, Caliper Life Sciences, Cell Signaling Technology, 908 Devices, Cellaria, SeraCare, Synap Dx, Xenogen and Solect Energy. Hrusovsky is committed to education and serves on the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston.

Hrusovsky holds an M.B.A. from Ohio University and a B.S. in Mechanical Engineering from The Ohio State University. He received an Honorary Doctorate from Framingham State University for his vast contributions in life sciences and personal medicine. In addition, he helped build competitive strategy curriculum at the Institute for Strategy & Competitiveness at Harvard Business School. Follow Kevin Hrusovsky on Twitter @KevinHrusovsky and LinkedIn @KevinHrusovsky.

Martin Madaus, PhD

Chairman and Chief Executive Officer, Ortho Clinical Diagnostics

Martin brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Martin is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He holds a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, Germany.

Keith L. Crandell

Co-Founder & Managing Director, ARCH Venture Partners

Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Keith has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp., Eichrom Industries, Nanophase Technologies, and Illinois Superconductor. He serves on the board of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, and Ciespace, and also as a director of the Illinois Venture Capital Association. Keith holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

David Walt, PhD

Senior Investigator, Brigham and Women’s Hospital, Department of Pathology, Core Faculty Member-Wyss Institute, Harvard Medical School at Harvard University

David R. Walt is a member of the faculty at Harvard Medical School in the Department of Pathology at Brigham and Women’s Hospital, is a Member of the Wyss Institute at Harvard University and is a Howard Hughes Medical Institute Professor. Previously, he was University Professor at Tufts University. Dr. Walt is the Scientific Founder of Quanterix Corp and has co-founded several other life sciences startups including Illumina Inc., Ultivue, Inc. and Arbor Biotechnologies. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He has published over 300 papers and holds nearly 100 patents. He received a B.S. in chemistry from the University of Michigan and a Ph.D. in chemical biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.

Paul Meister

Co-founder, Liberty Lane Partners, LLC

Paul is co-founder of Liberty Lane Partners, LLC, a private investment company with diverse investments in healthcare and distribution-related industries. He is also Chairman and Chief Executive Officer of inVentiv Health. Paul previously served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. During his tenure as an executive officer of Fisher Scientific, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively, as operations grew from two countries to 27, and sales expanded into 140 countries worldwide. He is a director of LKQ Corporation, Scientific Games Corporation, co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Paul holds an M.B.A. from Northwestern University.

Marijn Dekkers

Chairman of Novalis LifeSciences

Marijn E. Dekkers is founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry that he founded in 2017. From 2010-2016, Dr. Dekkers served as CEO of Bayer AG in Leverkusen, Germany. From 2002-2009, he was CEO of Thermo Fisher Scientific in Waltham, MA, USA. He started his career in 1985 as a research scientist at General Electric’s Corporate R&D Center in Niskayuna, NY, USA. Dr. Dekkers received his PhD and M.S. in Chemical Engineering from the University of Eindhoven and his B.S in chemistry from the Radboud University, both in the Netherlands. He holds dual U.S. and Dutch citizenship.

Sarah Hlavinka

Senior Vice President and General Counsel, Itron

Hlavinka brings to the Quanterix Board more than 25 years of experience as a senior advisor and business executive growing and scaling a variety of enterprises in the IT, service, manufacturing and healthcare industries. She currently serves as senior vice president and general counsel at Itron (NASDAQ: ITRI), which enablesutilities and cities to safely, securely and reliably deliver critical infrastructure services to communities in more than 100 countries. Prior to Itron, Hlavinka served as executive vice president, general counsel and secretary at Xerox Corporation. Previously, she has served in various corporate legal roles in companies including Fisher Scientific International, Benchmark Electronics, Hewlett Packard Company and Cooper Industries. Hlavinka earned her B.A. in history, Spanish minor from Texas A&M University and received her law degree from the University of Texas School of Law.

Open Positions

Development

Senior Program Manager / Program Manager

Billerica, MA

Senior Program Manager / Program Manager

Remote

Distribution

Manager, Materials and Logistics

Billerica, MA

Engineering

Mechanical Engineering Coop (Spring 2020)

Billerica, MA

Mechanical Engineering Coop (Spring 2020)

Gothenberg, Sweden

Field Service

Field Service Engineer – Southern Germany

Tubingen, Germany

Field Service Engineer – Milan

Milan, Italy

Field Service Engineer – Gothenberg

Gothenberg, Sweden
Measure biomarkers at lower levels than ever before

Reverse Phase Protein Array

With Simoa Senstivity™, Quanterix’ Planar Array Technology now gives researchers an incredibly simple, flexible, robust, and sensitive multiplex immunoassay platform for measuring biomarkers in most common sample types.

  • Proprietary, high-precision, digital nanofluidic antibody deposition
  • Unique spot design
  • Reaction kinetics optimized by fluid dynamics
  • Optimized image quality & dynamic range
Measure biomarkers at lower levels than ever before

SIMOA® Bead Technology

Quanterix’ digital biomarker detection technology, Simoa®, is changing the way in which the biology of health and disease is studied by giving researchers the ability to examine critical proteins and nucleic acids, at ultra low – even baseline – levels, in most common sample types.

  • First of its kind detection capabilities
  • Detect biomarkers at femtogram levels
  • See results in record time
download brochure
How it works

A high level look at a Simoa Bead-based assay, from development to data analysis.

1

Paramagnetic particles coupled with antibodies designed to bind to specific targets are added to the sample.

Carousel Image 1
2

Detection antibodies – capable of generating fluorescent product – are added.

Carousel Image 2
3

The objective is to form an immunocomplex consisting of the bead, bound protein, and detection antibody.

Carousel Image 3
4

4 Detection antibodies – capable of generating fluorescent product – are added.

Measure biomarkers at lower levels than ever before

SIMOA® Planar Array

An incredibly simple, flexible, robust, and ultra-sensitive immunoassay platform for measuring up to 10-plex biomarkers. Its unique capabilities are designed specifically to address many of today’s unmet needs in immuno-oncology and other research areas.

  • Proprietary, high-precision, digital nanofluidic antibody deposition
  • Reaction kinetics optimized by fluid dynamics
  • Optimized image quality and dynamic range
download brochure
How it works

A high level look at a Simoa Planar Array assay, from initiation to imaging.

1

96-well plates are spotted at the factory with the target analyte(s) of interest

2

Diluted samples and standards added to each well and the plates are to create a unique surface chemistry and “vortex” effect

3

Biotinylated detection antibodies are added to form the other half of the immunocomplex “sandwich”

4

4 Diluted samples and standards added to each well and the plates are to create a unique surface chemistry and “vortex” effect

Scientific Principle of Single Molecule Array Technology

Single-molecule analysis provides a resolution that simply cannot be obtained with bulk ensemble measurements. Single molecule measurements are digital in nature:

Each molecule generates a signal that can be counted. It is much easier to measure the presence or absence of signal than to detect the absolute amount of signal — that is, counting is easier than integrating.

Quanterix has developed an approach for detecting thousands of single protein molecules simultaneously. Using the same reagents as a conventional ELISA, this method has been used to measure proteins in a variety of different matrices at femtomolar concentrations. This approach makes use of arrays of femtoliter-sized reaction chambers, which are termed single-molecule arrays (SimoaTM), that can isolate and detect single enzyme molecules. Because the array volumes are approximately 2 billion times smaller than a conventional ELISA, a rapid buildup of fluorescent product is generated if a labeled protein is present. With diffusion defeated, this high local concentration of product can be readily observed. Only a single molecule is needed to reach the detection limit.

Quanterix Iceberg Image

The Evolution of the Immunoassay

Revolutionizing new discoveries with ultra-sensitive detection. Enable detection of thousands more targets for drug development, efficacy and safety.

learn more
Quanterix Iceberg Image

Leverage Simoa for PK/PD, Efficacy, Safety and Target Engagement with the Highest Possible Sensitivity.

With the Simoa® Accelerator Laboratory as your pharma service technology solution of choice, you can expand the limits of biomarker exploration and dramatically accelerate the timeline to drug approvals.

The Simoa Accelerator Laboratory is a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. Our state-of-the-art facility includes a CLIA-certified lab and puts the power of groundbreaking Simoa technology to work to achieve research objectives for over 160 pharma and academic customers from all over the globe. As the innovators of the Simoa platform, the Accelerator Laboratory has completed more than 400 Simoa projects and well over 100,000 samples run to date – more than any other lab in the world.

Quanterix’ team of dedicated scientists offer the greatest depth of instrument experience and ultra-sensitive assay development – all the way through manufacturing – giving you instant access to Simoa technology. From expert and rapid development of custom assay kits, to selection of best antibody pairs, to running sample sets of any size, The Simoa Accelerator Lab treats every project with individualized attention to help your organization achieve its research and development goals efficiently and cost-effectively.

Why Choose Simoa Laboratory:

  • CLIA-Certified Laboratory
  • Offers the technology for single-plex and multiplex detection of proteins and nucleic acids, at ultra-sensitive levels
  • Provides the ability to use your proprietary antibodies/reagents or one of our extensive range of commercially-available assays
  • Infrastructure allows scalability to handle sample sets from one plate to thousands of samples
  • Develops robust SOPs and LIMS for project/sample tracking
  • Delivers quick turn-around with the flexibility to adjust project scope
  • Onsite assay development training available through a comprehensive, 4-day program

Already Working With Our Accelerator Team?

SIMOA Accelerator Leadership Team

Mark Roskey, Ph.D.

Senior Vice President, Commercial & Assays

David Hanlon, Ph.D.

Vice President, Accelerator and Pharma Services 2

Dan Sikkema, Ph.D.

Vice President, Accelerator and 3Pharma Services

Mary Ellen Cortizas, , JD

Vice President 4

Mark Roskey, Ph.D. 2

Vice President, Accelerator and Pharma Services 5

meet the team

SIMOA® HD-X Analyzer

Introducing the world’s most sensitive, fully automated immunoassay platform with multiplexing and custom assay capability

request a quote

HD-X Analyzer™ tab thumbnail

HD-X Analyzer™

Introducing the world’s most sensitive, fully automated immunoassay platform with multiplexing and custom assay capability.

HD-X Analyzer™ tab thumbnail

1000x

Up to 1000x greater sensitivity

6 in 1

Up to 6 biomarkers in a single assay

80+

Compatible with 80+ assays

request a quote
SP-X Imaging and Analysis System™ tab thumbnail

SP-X Imaging and Analysis System™

Unleashing the power of next-generation Simoa® Planar Array technology for robust multiplex biomarker detection – even at healthy baseline levels.

SP-X Imaging and Analysis System™ tab thumbnail

1000x

Up to 1000x greater sensitivity

10 in 1

Up to 10 biomarkers in a single assay

100+

Compatible with 100+ assays

request a quote
SR-X™ Biomarker Detection System tab thumbnail

SR-X™ Biomarker Detection System

Offers researchers access to ultra-sensitive biomarker detection capabilities in a compact and affordable system.

SR-X™ Biomarker Detection System tab thumbnail

1000x

Up to 1000x greater sensitivity

6 in 1

Up to 6 biomarkers in a single assay

30+

Compatible with 30+ assays

request a quote
2470 Arrayer tab thumbnail

2470 Arrayer

Produces high quality microarrays of DNA, proteins, cell lysates and a variety of other samples using its proprietary soft touch deposition technology.

2470 Arrayer tab thumbnail

Flexible

Unmatched sample flexibility

Versatile

Prints on a variety of surfaces

Quality

High density printing for accuracy

request a quote

asdasdasd

asdasdasdasd asd asd asd

learn more

Ready to take your biomarker research to the next level?

request a quote
products

Quanterix Instruments

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean euismod bibendum laoreet.

SIMOA HD-X ANALYZER

Delivering Ultrasensitive Biomarker Measurement You Can Count On.

The latest model is a fully automated Simoa bead-based immunoassay platform. HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.

SIMOA SP-X

Single molecule detection in a benchtop instrument

Access Simoa-sensitive biomarker detection capabilities using the Simoa bead platform, in a compact, affordable system.

SIMOA SR-X

Single molecule detection in a benchtop instrument

Access Simoa-sensitive biomarker detection capabilities using the Simoa bead platform, in a compact, affordable system.

SIMOA 2470 Microarrayer

Quality, Reliability, Flexibility and True Walk-Away Automation in Mind

Produces high quality microarrays of DNA, proteins, cell lysates and a variety of other samples using its proprietary soft touch deposition technology.